Press release content from Business Wire. The AP news staff was not involved in its creation.
Charles River Partners with JADE Biomedical to Expand Biologics Capabilities
January 14, 2021 GMT
WILMINGTON, Mass. & SHANGHAI (BUSINESS WIRE) Jan 14, 2021
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with JADE Biomedical (JADE), a provider of end-to-end quality management services for the biopharmaceutical industry. The partnership will expand Charles River’s biologics testing capabilities geographically and help to accommodate demand for biologics therapeutics, especially cell and gene therapies, reaffirming the company’s commitment as a global development partner. This strategic relationship will also enable JADE to expand their current global Good Manufacturing Practice (GMP) product testing operations in Shanghai into a second facility and further build upon its current offering of comprehensive biol
Share this article
Share this article
SEOUL, South Korea, Jan. 12, 2021 /PRNewswire/ Hanmi Pharmaceutical Co., Ltd., announced endless challenges and new commitments for the pharmaceutical industry as their management slogan for the new year, presenting the business direction for the year 2021 at the 39th JP Morgan Healthcare Conference, which was held online.
Hanmi Pharmaceutical Co., Ltd Bio Plant manufacturing and Development facilities.
A view of the Pyeongtaek Bio Plant of Hanmi Pharmaceutical Co., Ltd.
During the day s presentation, Hanmi Pharmaceutical Co., Ltd. drew attention by going public with their global strategy and a solution package for coping with COVID-19 for the first time, along with their presentation on specific vision for the existing pipeline that will lead to innovative new drugs.
DiNAQOR Establishes New GMP Manufacturing Facility in Zurich
News provided by
Share this article
Share this article
PFÄFFIKON, Switzerland, Jan. 11, 2021 /PRNewswire/ DiNAQOR, a gene therapy platform company, today announced that it will establish its own GMP manufacturing capabilities with a new facility in the Bio-Technopark Schlieren-Zürich. This state-of-the-art 1200 sqm (13,000 sq. ft) GMP facility will produce adeno-associated virus (AAV)-based gene therapies and is co-located with DiNAQOR s Research & Development (R&D) facility. Establishing DiNAQOR s own gene therapy manufacturing capabilities positions us for the successful development of our in-house pipeline of novel genetic treatments for the failing heart, said Eduard Ayuso, D.V.M., Ph.D., Chief Technology Officer at DiNAQOR. By building our new GMP facility alongside our R&D facility, DiNAQOR will have R&D, Process and Analytical Development, Quality Control and GMP capabilities in the same location, en